close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Cetero Research Adds DGD Research, Enhancing Their Therapeutic Capabilities and Expertise to Include Endocrinology and Metabolic Disorders

CARY, N.C.--(BUSINESS WIRE)--Jan 8, 2008 - Cetero Research, the world's largest provider of early clinical and bioanalytical research services for the pharmaceutical industry, has enhanced their therapeutic research capabilities and expertise with the addition of DGD Research (formerly Diabetes & Glandular Disease Research Associates), a San Antonio, TX-based, contract research organization.

Since January 2006, Cetero has built a world-class team of early clinical and bioanalytical sites strategically located throughout North America, with six clinical sites in St. Louis, MO, Fargo, ND, East Grand Forks, MN, Miami, FL, Toronto, Ontario, Montreal, Quebec, and three bioanalytical laboratories in Houston, TX, Fargo, ND, and Toronto, Ontario.

Cetero currently has therapeutic capabilities in Immunology, Respiratory, Dermatology, Endocrinology and Cardiovascular. The addition of DGD Research to Cetero significantly increases access to patient populations with endocrinology and metabolic disorders, including: diabetes, heart disease, hypogonadism, growth hormone deficiency and hypothyroidism. The merger adds a new, 80,000 sq. ft. purpose-built research facility with 100 Phase I beds, with 12 dedicated Euglycemic/Hypoglycemic Clamp beds.

"The addition of DGD Research to the Cetero family provides unrivaled experience with patient populations to our Phase I-IV capabilities in therapeutic research, especially within the endocrinology and metabolic disorder areas," said Jerry Merritt, CEO of Cetero Research. "With more than 3,000 patients recruited each year to participate in clinical trials at the DGD clinic, the strong scientific rigor and patient-centered philosophy of DGD is core to the Cetero vision of today's research for tomorrow's healthcare."

Cetero's expertise is unparalleled in the early clinical research and bioanalytical industry with a foundation of more than 24 years of experience - offering a full spectrum of services from early clinical research through late stage to meet the needs of biotechnology, generic and pharmaceutical companies globally. Cetero provides quality research services including: clinical pharmacology, bioanalytical, integrated bioequivalence, cardiac safety, pre-clinical and clinical dermatology, environmental exposure chambers, central laboratory and late stage clinical trial management.

"Becoming part of the Cetero family of companies only enhances DGD's opportunity to positively impact the welfare and education of the public -- our original mission," said Sherwyn L. Schwartz, MD, CEO and CMO of DGD Research. "Joining Cetero will allow us to offer more comprehensive services to our clients, including: pharmacokinetics, pharmacodynamics, data management and report writing services."

Headquartered in San Antonio, TX, DGD Research was established in 1983 by Dr. Sherwyn L. Schwartz, M.D., as an addition to the Diabetes & Glandular Disease Clinic -- one of the largest endocrinology practices in the United States. With Drs. Jerome S. Fischer, M.D. and Mark S. Kipnes, M.D., DGD Research has performed more than 1,500 Phase I-IV clinical trials in diabetes, hypertension, neuropathy, osteoporosis, hypercholesterolemia, obesity, menopause, and nephropathy under the supervision of major pharmaceutical companies in accordance with FDA rules and regulations. Currently, DGD Research has two clinical sites in San Antonio and leads the U.S. market in Phase I endocrine/metabolic clinical trials and is fifth nationwide for Phase II-IV trials.

Cetero Research's corporate headquarters are located in Cary, NC. For more information on Cetero Research, please contact April Johnson at 919-468-4214 or visit www.cetero.com/dgd.

Contact

Cetero Research
April Johnson, 919-468-4214
www.cetero.com/dgd

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...